SCYNEXIS Acquires Poxel’s PXL-770 for ADPKD, Plans 2026 Phase 2 Trial

Overview

• SCYNEXIS, which announced the transaction Tuesday, signed a definitive agreement to buy PXL-770 from Poxel and renamed the asset SCY-770 for Autosomal Dominant Polycystic Kidney Disease.
• The terms include an $8 million upfront payment, up to $8 million in development milestones, and up to $180 million in commercial milestones, with $125 million tied to at least $1 billion in annual net sales.
• The company plans a Phase 2 proof‑of‑concept study in the fourth quarter of 2026 with an early efficacy readout expected in the second half of 2027.
• In a separate move disclosed Tuesday, SCYNEXIS arranged a $40 million private placement expected to close on or about April 1, 2026, which it says will fund operations into mid‑2029.
• SCY‑770 is a direct AMPK activator designed to slow kidney cyst growth in ADPKD, a disease affecting about 140,000 people in the U.S. that currently has only one approved therapy with safety and tolerability limits.